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Abstract
Danger-associated molecular patterns (DAMPs) are host-derived molecules that can function to regulate the
activation of pathogen recognition receptors (PRRs). These molecules play a critical role in modulating the
lung injury response. DAMPs originate from multiple sources, including injured and dying cells, the extracellular
matrix, or exist as immunomodulatory proteins within the airspace and interstitium. DAMPs can function as
either toll-like receptor (TLR) agonists or antagonists, and can modulate both TLR and nod-like receptor (NLR)
signalling cascades. Collectively, this diverse group of molecules may represent important therapeutic targets in
the prevention and/or treatment of acute lung injury (ALI) and its more severe form, acute respiratory distress
syndrome (ARDS).
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Introduction
The lung is continuously exposed to the external envi-
ronment and the entirety of the circulating blood vol-
ume. As a result, this organ is constantly bombarded
with potentially injurious agents. These noxious stim-
uli include exogenous signals, such as microbial and
environmental antigens, as well as a plethora of host-
derived danger signals. A common final pathway ini-
tiated by these exogenous and endogenous triggers
is the development of acute lung injury (ALI). ALI
and its more severe form, acute respiratory distress
syndrome (ARDS), are characterized by an initial
exudative phase, which is triggered by the release
of inflammatory cytokines [tumour necrosis factor-
α (TNFα), interleukin-1β (IL-1β)] and chemokines
(CXC, CC and CX3C) and the influx and activation
of inflammatory leukocytes. These events culminate
in injury to the alveolar–capillary membrane, result-
ing in flow of proteinacious fluid and debris from the
pulmonary vasculature space into the lung interstitium
and ultimately the alveolar space [1]. The prolifera-
tive phase of ALI is characterized by organization of
interstitial and alveolar exudates and the beginning
of alveolar epithelial and endothelial repair. During
this phase, fibroblasts migrate to the basement mem-
brane and depose extracellular matrix (ECM) compo-
nents, including collagen, fibronectin and hyaluronan
[2,3]. The majority of patients spontaneously resolve
this inflammatory insult. However, nearly one-third
of patients will progress to the fibrotic phase of
ALI/ARDS. In these patients, chronic respiratory fail-
ure is common and mortality is increased [4].
Pathogen recognition receptors
The primary pathway by which the innate immune sys-
tem is alerted to the presence of noxious stimuli is
through pattern recognition receptors (PRRs). Pathogen
recognition receptors are activated by both exogenous
pathogen-associated molecular patterns (PAMPs) and
endogenous danger (or damage)-associated molecu-
lar patterns (DAMPs) [5]. Microbial components (eg
PAMPs) that are present during infection can induce
lung inflammatory responses and injuries that are medi-
ated through Toll-like receptors (TLRs), nucleotide-
binding oligomerization domain (NOD)-like receptors
(NLRs) and retinoic acid-inducible gene I (RIG-I; RAR-
RES3 ) pathways [6]. Activation of these PRRs pro-
motes inflammatory cytokine expression and antimi-
crobial pathways that are required for microbial clear-
ance. However, inadequately controlled inflammation
can result in cell death by necrosis, apoptosis, pyrop-
tosis or autophagy. Of these death pathways, necrosis is
the most immunogenic, due to the massive and unreg-
ulated release of DAMPs that stimulate both TLR and
non-TLR pathways, leading to heightened inflamma-
tion and tissue remodelling [7,8]. The DAMP–TLR
interaction can be direct, as is the case with fibronectin
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Figure 1. Schematic depicting TLRs and their respective DAMPs: Hsps, heat shock proteins; HA, hyaluronan; HMGB1, high-mobility group
box 1; SP-A, surfactant protein A; SP-D, surfactant protein D
Figure 2. Schematic of MyD88-dependent TLR pathway activation
in response to PAMPs and DAMPs
and hyaluronan, which serve as TLR agonists to initiate
inflammatory cascades, or indirect, as observed with
some heat shock proteins that interact with co-activator
molecules to augment TLR signalling [9–11]. High-
mobility group box 1 (HMGB1) can act directly with
TLR2 and TLR4 to promote inflammation, and can also
bind DNA to facilitate co-localization with respond-
ing TLRs (eg TLR9) [12–15]. Alternatively, there are
some DAMPs, specifically surfactant protein A (SP-
A) and possibly surfactant protein D (SP-D), which
act to suppress TLR signalling and restore homeosta-
sis through blocking interactions between TLRs and
agonist molecules [16,17]. In cases of infectious and
non-infectious lung injury, DAMPS can mediate both
inflammatory and anti-inflammatory effects [18] (see
Figure 1).
TLRs in ALI
TLR signalling pathways play a key, but complex,
role in the pathogenesis of ALI. Upon ligand bind-
ing, stimulation of the majority of TLRs (except
TLR3) promotes myeloid differentiation primary
response gene 88 (MyD88)-dependent activation
of IL-1 receptor-activating kinase 1/4 (IRAK-1/4),
which culminates in mitogen activating protein kinase
(MAPK) activation and translocation of nuclear factor
kB (NF-kB) p65 into the nucleus [5]. NF-kB promotes
transcriptional activation of genes encoding inflam-
matory cytokines and chemokines, while the MAPK
pathway not only induces pro-inflammatory cytokine
production but also stimulates cell proliferation and
survival [5,19] (see Figure 2). TLRs have been shown
to promote inflammatory cell recruitment and activa-
tion in both infectious and non-infectious lung injury
models, a corollary to the exudative phase of ARDS
[6]. However, these same TLRs are also required to
maintain the integrity of the alveolar–capillary mem-
brane during ALI. For instance, genetically mutant
mice with defective TLR4 signalling [TLR4lps/d
(Balb/c) mice] developed increased capillary leak
and alveolar epithelial cell (AEC) apoptosis dur-
ing Gram-negative pneumonia, which was due, in
part, to impaired production of the cytoprotective
cytokine granulocyte macrophage colony-stimulating
factor (GM-CSF) within the airspace [20]. In the
non-infectious bleomycin model of ALI, TLR2/TLR4
double-deficient mice had less lung inflammation
yet experienced higher mortality, more severe
alveolar–capillary leaks and greater AEC apoptosis,
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 145–156
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
DAMPs in ALI 147
Table 1. Endogenous ligands of Toll-like receptors and Nod-like receptors and their physiological effects
DAMP Receptor Effect
ECM components
Fibronectin TLR4 Increase NF-kB, promote leukotriene synthesis and PMN
migration, activate the adaptive immune system
Hyaluronan TLR4± TLR2, NLR3 Induce proinflammatory cytokines, activate DCs and
macrophages
Heparan sulphate TLR4 Increase TNFα expression, activate DCs
Stress-response molecules
Heat shock proteins TLR2, TLR4 Induce cytokines and protein kinases, activate PMNs
HMGB1 TLR2, TLR4 Induce NF-kB nuclear translocation and cytokine expression
Nucleic acids TLR3, TLR7, TLR9 Induce cytokine expression, activate DCs, stimulate
recruitment of leukocytes and PMNs
microRNA TLR8 Induce NF-kB and cytokines expression
Immunomodulatory proteins
β-Defensins TLR1/TLR2, TLR4 Induce NF-kB and cytokine expression, activate DCs and
monocytes
Surfactant protein A TLR4± TLR2 Reduce NF-kB and cytokine expression
Surfactant protein D TLR2, TLR4 Inhibit cytokine production and recruitment of PMNs
Others
Uric acid NLR3 Increase IL-1β expression
implying that TLR2 and/or TLR4 promote pro-survival
effects on the alveolar epithelium [21]. Similarly,
in hyperoxia-induced ALI, TLR4-deficient mice are
more susceptible to lung injury, due to increased
epithelial and endothelial apoptosis and decreased
expression of the antioxidant heme oxygenase-1
[22,23]. Conversely, TLR3 has been shown to mediate
lung injury responses during exposure to high oxygen
tensions. For instance, TLR3-deficient mice were
protected from lung injury and had increased survival
after hyperoxic exposure in vivo, and TLR3-deficient
AECs were less susceptible to hyperoxia-induced ALI
[24]. Collectively, this implies that the role of TLRs
in ALI is highly contextual and TLR-specific.
DAMPs
DAMPs are host-derived molecules that can function
to regulate the activation of PRRs. In general, various
DAMPs can be subdivided into three broad categories:
(a) ECM components; (b) molecules released during
cellular stress; and (c) secreted immunomodulatory
proteins. ECM components that can activate TLRs
include fibronectin and hyaluronan. Stress-response
molecules, including heat-shock proteins (HSPs),
HMGB1 and nucleic acids that are secreted by cells
or released when cells die compose the second cate-
gory. The final category includes immunomodulatory
proteins, such as β-defensins and surfactant proteins,
that are involved in a variety of biological processes,




Fibronectin (MW ∼450 kDa) is an extracellular gly-
coprotein adhesion molecule that exists in soluble
(plasma) and insoluble (cellular) forms. The soluble
isomer is a major component of blood, whereas the
insoluble form is a major component of the ECM [26].
Fibronectin is involved in many physiological pro-
cesses, but primarily functions in regulating cellular
adhesion, migration, proliferation and wound healing
[27,28]. This protein has also been shown to regulate
immune responses by binding to and activating sev-
eral TLRs. Specifically, fibronectin has been shown to
activate HEK 293 cells transfected with TLR4, but not
in non-transfected cells. Stimulation with fibronectin
extra domain A (EDA) in TLR4 expressing HEK cells
resulted in increased expression of NF-kB, similar in
magnitude to that observed with lipopolysaccharide
(LPS) stimulation [9]. Additional studies have con-
firmed the ability of fibronectin to activate TLR4 in a
variety of cell populations and in vivo models [29,30].
Newer data suggest that fibronectin–TLR4 interactions
may serve as a positive feedback loop to amplify
inflammatory responses [31].
Fibronectin is a major cell-signalling molecule in
various forms of acute lung injury. Fibronectin mRNA
and protein levels are elevated in bronchoalveolar
lavage fluid (BALF) macrophages and alveolar epithe-
lial, interstitial and endothelial cells of animals with
hyperoxia-induced lung injury [32–34]. Similarly,
fibronectin mRNA and protein are most prominently
expressed during the exudative phase of bleomycin-
induced ALI [35,36]. In addition, fibronectin has been
implicated as a mediator of deleterious inflamma-
tion in other ALI models, including oxidant injury,
pancreatitis-induced ALI and injury from inhaled pul-
monary irritants, such as ozone [37–39]. Consistent
with experimental animal data, autopsy studies report
elevated amounts of fibronectin in the lungs of patients
who have died from ARDS, as compared to patients
without underlying lung disease who died of non-
pulmonary causes [40]. While there is clear evidence of
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 145–156
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
148 LB Tolle and TJ Standiford
robust fibronectin expression in both human and exper-
imental ALI, data implicating TLR4 or other TLRs in
mediating fibronectin’s biological effects are lacking.
Hyaluronan
Hyaluronan (HA; MW 2000–4000 kDa) is a non-
sulphated glycosaminoglycan that resides in the ECM
and acts as a moderator of lung water, as well as a
matrix glue for other connective tissue components
and cells [41]. During homeostasis, HA exists as a
high molecular weight (HMW HA) polymer (1–6 ×
106 Da) that undergoes continuous remodelling, result-
ing in degradation to lower molecular weight forms
(0.1–0.5 × 106 Da). The low molecular weight (LMW
HA) forms are immunologically active and are associ-
ated with diverse inflammatory conditions and/or tissue
injury [21,41]. Low molecular weight fragments of
HA have been shown to activate dendritic cells (DCs)
and macrophages to express inflammatory cytokines,
including IL-1β, TNFα and interleukin 12 (IL-12) [42].
The expression of inflammatory cytokines and cell mat-
uration was abrogated in HA-stimulated DCs isolated
from Tlr4-deficient but not Tlr2-deficient mice, imply-
ing that TLR4 is the effector PRR for HA-induced
DC effector responses [10]. Likewise, HA-mediated
responses in dermal endothelial cells were shown to be
TLR4-dependent [43]. However, other studies suggest
that LMW HA is a ligand for both TLR4 and TLR2.
For example, reduced expression of the chemokine
macrophage inflammatory protein 2 (MIP-2; Cxcl2)
was noted in peritoneal macrophages isolated from
Tlr2−/− and Tlr4−/− single-deficient mice in response
to HA. Chemokine expression was completely abol-
ished in Tlr2−/−/Tlr4−/− double-deficient macrophages
in response to HA, indicating that TLR2 and TLR4
serve as the predominant TLRs responding to HA [21].
Interestingly, while HA clearly initiates an inflam-
matory response in manner that is dependent on TLR
activation, this molecule appears to play a more com-
plex role in regulating lung injury responses in vivo.
As might be expected, administration of bleomycin
to Tlr2−/−/Tlr4−/− double-deficient mice resulted in
reduced influx of BAL neutrophils. Despite reduced
lung inflammation, there was increased lung injury
and mortality in Tlr2−/−/Tlr4−/− double-deficient
mice challenged with bleomycin, which correlated
pathologically with enhanced AEC apoptosis in
TLR double-deficient mice. AECs from these mice
produced less HMW HA compared to control cells,
and CC10-driven constitutive expression of HMW HA
in lung epithelial cells protected them from apoptosis
[21,44]. The mechanism by which HA-induced TLR
activation reduced epithelial cell apoptosis was not
completely defined, but was thought to be attributable
to low-level NF-κB activation and induction of
anti-apoptotic molecules, such as B-cell lymphoma 2
(Bcl2). Studies in various animal models have shown
that bleomycin-induced ALI causes elevated levels
of HA in BALF and alveolar interstitial tissue and
that this mirrors the increased amounts of pulmonary
oedema seen in ALI/ARDS [45–48].
Similar to the bleomycin model, TLR4 alone or
TLR2 and TLR4 in combination mediate protec-
tive effects on alveolar epithelium in hyperoxic lung
injury. It was noted that Tlr4−/−, and especially
Tlr2−/−/Tlr4−/− double-deficient, mice exposed to
hyperoxic conditions displayed more evidence of dif-
fuse alveolar damage and decreased survival [21].
Increased AEC apoptosis was observed in Tlr4-
deficient mice, which was due to an inability to up-
regulate the anti-apoptotic molecules Bcl2 and heme
oxygenase 1 (HO-1; Hmox1). Although HA is likely
functioning as aTLR agonist in this model, the specific
contribution of HA or other DAMPs was not defini-
tively established.
It is probable that HA contributes to lung injury
responses in patients with ALI/ARDS. For example,
an approximately six-fold increase in BALF HA levels
has been noted in ARDS patients as compared to
control subjects. Moreover, serum levels of HA were
30-fold higher in ARDS patients than in controls. There
was an inverse relationship between levels of HA and
PaO2:FiO2, substantiating a possible protective role
of HA in ALI [49]. Whether the potential protective
effects of HA in patients with ALI are mediated
through TLR2 and/or TLR4 has not been clarified.
Heparan sulphate
Heparan sulphate is a sulphated glycosaminoglycan
ECM protein functioning to localize cytokines or mod-
ify the activity of cytokines, proteases, growth factors
and other ECM proteins within the inflammatory
milieu [50]. There is compelling evidence that heparan
sulphate can activate DCs in a fashion similar to TLR
ligands, such as LPS and CpG DNA. Treatment of bone
marrow DCs derived from wild-type mice with heparan
sulphate stimulated DC maturation, which was signifi-
cantly mitigated by co-incubation with a selective phar-
macological TLR4 inhibitor [51]. Furthermore, signif-
icantly improved survival, associated with abrogated
serum TNFα responses, were observed in Tlr4-deficient
mice challenged with heparan sulphate intraperi-
toneally (i.p.), as compared to similarly treated wild-
type control animals [52]. Taken together, these find-
ings indicate that heparan sulphate promotes inflam-
matory responses in manner that is at least partially
dependent upon TLR4. There are no data to implicate
heparan sulphate as a relevant TLR agonist in exper-
imental models of ALI or patients with ALI/ARDS.
Stress response molecules
Heat shock proteins
Heat shock proteins (HSPs) are a group of molecules
that directly mediate protein folding or serve as molec-
ular chaperones that bind to nascent polypeptides and
partially folded intermediates, preventing aggregation
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and misfolding [53]. These molecules are primarily
intracellular proteins whose expression is constitutively
repressed under homeostatic conditions. During times
of physiological stress (i.e. inflammation, infections,
malignancy, etc.), gene expression is increased and
HSPs are released into the extracellular compartment.
HSPs are also released from necrotic cells and pro-
mote inflammation via the induction of multiple pro-
inflammatory cytokines [53,54]. Stimulatory effects on
cytokine production requires TLR4, as stimulation of
bone marrow macrophages derived from Tlr4 mutant
C3H/HeJ mice stimulated in vitro with heat shock pro-
tein 60 (Hsp60; Hspd1) displays reduced production
of TNFα and nitric oxide (NO), as compared to the
robust response observed in wild-type C57BL/6 cells
[55]. Additional studies performed in human embry-
onic kidney fibroblasts transfected with TLR2 or TLR4
indicate that Hsp 60, in combination with the co-
stimulatory molecule MD-2, uses TLR2 and TLR4 to
activate the toll–IL-1 receptor (TIR) signalling path-
way to induce inflammatory responses mediated by
multiple protein kinases [11]. Similarly, heat shock
protein 70 (Hsp70) induces inflammatory cytokine
production via MyD88–NF-kB–TIR pathways, utiliz-
ing both TLR2 and TLR4 for signal transduction in
human peripheral blood monocytes and RAW264.7
macrophages [56,57]. Heat shock protein Gp96 (Gp96)
has been shown to mediate NF-kB activation through
a TLR2–TLR4 pathway in bone marrow-derived DCs
that were lacking TLR2, TLR4 or both, whereas heat
shock protein 72 (Hsp72) induced the cytokines IL-
8 and TNFα through a TLR4-dependent mechanism,
as shown in human HL-60 cells treated with TLR4
neutralizing antibody and neutrophils isolated from
C3H/HeJ mice [58,59]. Relevant to lung inflamma-
tory responses, Hsp72 induced IL-8, TNFα and KC
in mouse lung epithelial cells, and this induction was
negated when assessed in TLR4-deficient cells or in
the presence of NF-kB inhibition [60].
In infectious models of ALI, the inflammatory
properties of HSPs seem to have a protective role if
administered before infectious challenge but become
cytotoxic if elevated or exogenously administered after
microbial exposure [61]. The role of HSPs in reg-
ulating non-infectious lung injury is less clear, as
there are limited studies in experimental models of
lung injury, including bleomycin. Data exist to sug-
gest that Hsp70 protects against bleomycin-induced
inflammation and injury. For example, bleomycin chal-
lenge in transgenic mice that over-express Hsp70
have reduced leukocyte recruitment to the lung, less
parenchymal cell apoptosis and reduced expression of
IL-1β, TNFα and IL-6 in BALF compared to wild-type
mice [62]. Similarly, Hsp70 protects human respiratory
epithelial cells from injury in the setting of hyper-
oxia, as cells over-expressing Hsp70 were shown to
be resistant to hyperoxia-induced cell death in vitro
[63]. It has not been established in the bleomycin
model whether Hsp70 is signalling through TLRs or
other receptors, and whether the protection observed
might be attributable to direct TLR-dependent pro-
survival effects on the respiratory epithelium. Con-
versely, Hsp27 expression was decreased in respira-
tory epithelial cells after exposure to 95% FiO2 and
was linked with less hyperoxia-induced apoptosis when
compared to controls, implying that there are disparate
effects of the various HSPs [64].
As a human correlate, airway epithelial cells iso-
lated from healthy patients inhaling 100% oxygen show
increased expression of genes encoding Hsp70. Induc-
tion of Hsp70 genes has also been observed in human
airway epithelial cells exposed to > 98% oxygen in
vitro [65]. In patients with ARDS, levels of Hsp72
were higher in pulmonary oedema fluid as compared to
those with hydrostatic pulmonary oedema, suggesting
that Hsp72 is produced or released within the alveolar
space in ALI [66]. There are no data to suggest that
levels of Hsp72 correlate with morbidity or mortality
in ALI patients. By comparison, serum Hsp60 levels
correlated positively with the development of ALI in
severe trauma patients [67]. This suggests that selected
HSPs may not only regulate lung injury responses in
a TLR-dependent fashion, but could also serve as a
marker for ALI development in at-risk patients.
High-mobility group box 1 (HMGB1)
HMGB1 is a highly conserved intranuclear protein with
the primary function of flexing the DNA double helix
to allow for proper DNA orientation, so that transcrip-
tion factors can efficiently bind DNA [68]. The two
principle ways by which HMGB1 is released from
cells is through disorganized necrosis and active secre-
tion from a variety of immune and structural cells
[69]. Release of HMGB1 into the extracellular space
is known to promote inflammation via stimulation of
monocytes to release TNFα and other inflammatory
cytokines [70]. It was initially believed that HMGB1-
induced inflammation was mediated by the receptor
for advanced glycation end products (RAGE). How-
ever, subsequent studies in other cells or cell lines
suggested that signalling through RAGE may be a less
relevant pathway of inflammatory cytokine expression
[14,71–73]. For instance, the mechanism of action for
HMGB1-related inflammation in both neutrophils and
macrophages is mediated through a direct interaction
with TLR2 and TLR4, leading to increased TLR sig-
nalling and nuclear translocation of NF-κB as well
as enhanced expression of pro-inflammatory cytokines
[12,14,74]. These observations provide support for the
notion that HMGB1 is a central component of a pos-
itive feedback loop, via TLRs, to amplify and sustain
inflammation [75,76]. In total, the controversy regard-
ing the relationship between HMGB1 and TLRs may
be fuelled by the differential utilization of TLRs in
different tissues, species and cell lines [77].
There is strong evidence that HMGB1 promotes pul-
monary inflammation during ALI. The intratracheal
(i.t.) instillation of purified HMGB1 in mice resulted
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in alveolar oedema and neutrophil influx in associa-
tion with elevated levels of IL-1β, TNFα and MIP-2
in BALF. Histologically, these samples demonstrated
diffuse alveolar damage identical to the pathologi-
cal findings in ALI/ARDS [78]. Inflammatory effects
in this model were not entirely TLR4-mediated, as
inflammatory changes in response to HMGB1 were
still apparent in C3H/HeJ mice. The stimulation of
rat alveolar macrophages with HMGB1 has also been
shown to dose-dependently stimulate the expression
of inducible nitric oxide synthase (iNOS; Nos2). Ele-
vated levels of iNOS promoted further inflammation
in rat lungs after HMGB1-induced ALI [79]. In a
bleomycin model of ALI, increased levels of HMGB1
were found in the BALF of wild-type mice, peaking
7–14 days post-bleomycin. When compared to wild-
type mice, RAGE-deficient mice challenged i.t. with
bleomycin had similar numbers of BALF inflamma-
tory cells but reduced BALF protein levels, suggesting
that the HMGB1–RAGE pathway likely contributes
to the high-permeability state observed in bleomycin-
induced ALI [80]. Several other animal models of
non-infectious lung injury have also been associated
with elevated levels of HMGB1, such as acute pan-
creatitis and haemorrhage [81,82]. In haemorrhagic
shock, HMGB1-induced inflammatory effects on lung
endothelial cells and PMNs was abrogated in mice defi-
cient in Tlr4 [83,84].
Our understanding of HMGB1 biology in patients
with ALI is limited. One small study of patients with
sepsis-induced ALI noted that HMGB1 was higher
in epithelial lung fluid and plasma in ALI patients
compared to controls. These findings persisted during
both the acute and subacute phases of ARDS. Levels
of HMGB1 did not correlate with lung injury score
or mortality [85]. Additional studies are needed to
better define the contribution of HMGB1 and receptors
involved in this patient population.
Nucleic acids
Multiple studies have implicated nucleic acids from
bacterial and viral genomes as potent activators of
TLRs [86–89]. Human nucleic acids are located intra-
cellularly but are released into the extracellular envi-
ronment during cell necrosis and late apoptosis [90].
Once within the extracellular environment, these
nucleic acids can be modified and recognized as for-
eign, eliciting an innate immune response. Human
nucleic acids were first shown to be ligands for
TLR9 (DNA), TLR7 [single-stranded (ss) RNA] and
TLR3 [double-stranded (ds) RNA] when DNA and
RNA immune complexes were found to directly acti-
vate plasmacytoid pre-dendritic cells, resulting in
interferon-α (IFNα) production. Treatment with TLR7-
and TLR9-blocking antibodies dramatically decreased
INFα production in response to DNA and RNA com-
plexes, respectively [91]. Endogenous mRNA can stim-
ulate TNFα and TLR3 gene expression from human
DCs, as well as cell surface expression of the activa-
tional markers CD83 and HLA-DR. Moreover, endoge-
nous mRNA induced DCs to secrete elevated levels of
IL-12, IL-8 and IFNα, which was reversed in the pres-
ence of TLR3 blocking antibody [92]. Finally, using
genetically deficient mice, TLR3 was shown to mediate
many of the pathophysiological events in experimental
abdominal sepsis, an effect that was mediated by the
presence of cellular debris from necrotic PMNs (pre-
sumably nucleic acids) [93]. Thus, it appears that both
endogenous mRNA and DNA can stimulate the effec-
tor functions of DCs and potentially other cells, further
amplifying the innate immune response.
New research has provided additional insights into
the mechanism by which ’self’ DNA can activate
TLR9. Due to its high binding affinity for nucleic acids,
HMGB1 readily binds to host DNA and modulates
TLR-dependent inflammation [15,94,95]. HMGB1 may
do this by facilitating DNA:TLR9 trafficking to
the endosome and enhancing TLR9-dependent sig-
nal transduction [96]. Thus, the ability of endogenous
DNA to stimulate TLR9 is not only enhanced by chem-
ical modifications to the DNA (eg changes in CpG
methylation) but also by complexing with proteins that
promote DNA:TLR9 co-localization.
MicroRNAs are host-derived single-stranded RNA
species that modulate the expression of many genes
during inflammation, including during ALI [97,98].
MicroRNAs are induced by TLR activation and
post-transcriptionally regulate TLR-dependent gene
expression and signalling [99,100]. Emerging data, pri-
marily in cancer model systems, suggest that microR-
NAs can also bind and functionally activate certain
TLRs, such as TLR8 [101]. These observations support
the notion that microRNAs may function as relevant
TLR signalling modifiers in the setting of pulmonary
inflammation and injury. However, there are no data
implicating DNA, RNA or microRNA as relevant TLR




β-Defensins are small antimicrobial and cytotoxic pep-
tides that are produced during infection due to a vari-
ety of microbial organisms, including Gram-positive
and Gram-negative bacteria, mycobacteria, fungi and
enveloped viruses [102]. In addition to being a key
component of innate immunity, β-defensins have been
shown to be endogenous ligands for toll-like recep-
tors and function to augment the innate response.
Specifically, murine β-defensin 2 can stimulate bone
marrow-derived DCs to express cell surface CD11c and
the co-stimulatory molecule CD40. The inflammatory
cytokine profile expressed in response to β-defensin
2 was similar to that expressed by DCs in response
to LPS. In macrophages, the stimulatory effect of
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β-defensin 2 was TLR4-dependent, as neither LPS
nor β-defensin 2 were able to activate macrophages
obtained from Tlr4-deficient mice [103]. In addition
to stimulation of inflammatory cytokines in DCs, β-
defensin 2 may also promote early cell death, a pro-
cess mediated by TLR4/MyD88-dependent activation
of NF-κB. The implication of this work is that endoge-
nous β-defensin 2 may have a dynamic role in inflam-
mation; initially serving as a signal for immune cell
activation and later driving the elimination of activated
cells to prevent the long-term consequences of persis-
tent inflammation [104].
Human β-defensin 3 has also been shown to induce
cell surface co-stimulatory molecules on human periph-
eral blood monocytes in vitro. In experiments using
HEK 293 cells that were mutated to express various
TLRs, there was no interaction between any single TLR
in isolation with human β-defensin 3. However, when
these cells co-expressed TLR1 in combination with
TLR2, stimulation with human β-defensin 3 induced
NF-κB and this effect was blocked by antibodies to
TLR1 and TLR2 [105]. These intriguing findings sug-
gest that TLR1 and TLR2 can cooperatively respond
to human β-defensin 3, whereas neither in isolation is
sufficient to initiate this process.
A possible protective role of β-defensins has been
noted in sepsis-induced ALI. The over-expression of
β-defensin 2 in lung prior to an i.t. challenge with
Pseudomonas aeruginosa , or undergoing experimental
abdominal sepsis, resulted in reduced alveolar dam-
age, interstitial oedema and BALF neutrophilia [106].
In a rat intestinal ischaemia and reperfusion-induced
ALI model, high levels of β-defensin 2 were noted and
levels were inversely correlated with pulmonary per-
meability [107]. Whether this effect was mediated by
direct TLR activation was not addressed.
Pulmonary surfactant proteins
SP-A
Pulmonary surfactant is a lipoprotein complex that
functions to reduce surface tension within the alve-
oli and prevent alveolar collapse at end expiration.
Surfactant contains four specific proteins, surfactant
protein A (SP-A), SP-B, SP-C and SP-D. These pro-
teins play unique but complementary roles in surfac-
tant lipid metabolism, lipid membrane organization
and host defence [108]. SP-A and SP-D are mem-
bers of the collectin family, and have been shown to
directly interact with microbes such as bacteria and
viruses to inhibit proliferation and microbicidal activ-
ity and facilitate microbial uptake by macrophages
[109]. Early studies performed in a human acute
monocytic leukaemia cell line demonstrated that SP-
A dose-dependently activated the NF-κB pathway
in a similar manner to LPS, suggesting they may
share a common receptor [109]. In vitro stimulation
of bone marrow-derived macrophages from a Tlr4-
competent strain mice (C3H/HeOuJ) with SP-A dose-
dependently increased the expression of TNFα and the
anti-inflammatory cytokine IL-10 [110]. Conversely,
SP-A-induced inflammatory responses were abrogated
in macrophages isolated from an isogenic mutant Tlr4-
deficient (C3H/HeJ) mouse strain, indicating that TLR4
is a receptor for and is activated by SP-A [110].
While SP-A appears to be capable of directly activat-
ing TLR4, accumulating data suggest that this protein
can actually attenuate the activation of macrophages
in response to PAMPs, including LPS, peptidogly-
can and zymosan, and that this process is mediated
through the TLR2 or TLR4 pathways [17,111,112]. For
example, pre-treatment of alveolar macrophages with
SP-A blunted subsequent NF-kB activation and TNFα
production in response to either TLR2 or TLR4 ligands
[16,113]. The mechanism for this suppressive effect
has not been fully elicited, but one theory is that SP-A
binding to TLRs may block the ability of other PAMPs
to bind and initiate TLR-mediated inflammation [114].
Studies using non-infectious models of lung injury
have demonstrated that SP-A can reduce type II alveo-
lar cell apoptosis, although this effect does not appear
to be TLR-mediated [115]. The administration of
bleomycin to SP-A-deficient mice results in enhanced
recruitment of leukocytes, expression of inflammatory
cytokines (IL-1β, TNFα and KC), oedema formation
and apoptosis, as compared to wild-type mice [116].
This is consistent with the premise that SP-A acts to
reduce inflammation in acute lung injury.
Serum SP-A levels are elevated in patients with
ARDS, as compared to healthy controls and mechan-
ically ventilated control patients, and circulating
levels of SP-A may be of prognostic significance in
this disease. In a smaller series, serum SP-A levels
were inversely correlated with oxygenation and lung
compliance [117,118]. Conversely, a trial investigating
the influence of ARDSnet ventilation strategy on
biomarkers of lung injury failed to find any correlation
between plasma SP-A levels and clinical outcomes
[119]. It is unclear whether levels of SP-A in circu-
lation simply reflect the magnitude of permeability
change across the alveolar capillary membrane, or
rather that SP-A may have some causative role in
modulating the lung injury response.
SP-D
SP-D, like SP-A, can interact with TLRs. SP-D has
been shown to directly bind to TLR2 and TLR4,
although the biological impact of this interaction
was not described [120]. Importantly, pre-incubation
of rat alveolar macrophages with SP-D mitigated
LPS-induced inflammatory response [121]. Consistent
with anti-inflammatory effects of SP-D, SP-D-deficient
mice developed enhanced influx of BALF neutrophils,
increased total protein, and higher levels of inflamma-
tory cytokines (IL-1β, IL-6 and MIP-2) in response to
i.t. LPS administration. The exogenous administration
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of SP-D resulted in marked suppression of the inflam-
matory response. Similar results were noted when the
TLR2 agonist lipoteichoic acid (LTA) was used as the
inciting cause of ALI [122,123]. These findings indi-
cate that SP-D plays a protective and anti-inflammatory
role in LPS and LTA induced ALI.
Similar anti-inflammatory properties of SP-D have
been described in the bleomycin model of ALI. After
the i.t. instillation of bleomycin, serum levels of SP-D
were elevated, peaking on day 7 and coinciding with
the amount of inflammation seen in histological lung
samples [124]. There was a dose-dependent increase
in morbidity and mortality in SP-D-deficient mice
challenged with bleomycin, compared to wild-type.
Conversely, mice over-expressing SP-D in the lung
were highly resistant to bleomycin-induced morbidity
and mortality [125]. The mechanism of protection
conferred by SP-D in these model systems has not been
precisely defined. One can speculate that SP-D binding
to TLRs might antagonize interactions with other TLR
agonists in a fashion analogous to SP-A; however, this
hypothesis requires experimental validation.
In patients with ARDS, higher plasma SP-D levels
have been associated with increased risk of death,
fewer ventilator-free days and fewer organ failure-
free days.[119] In contrast, reduced pulmonary oedema
fluid SP-D in patients with ARDS was associated
with worse clinical outcome, substantiating a potential
protective role of SP-D in ALI/ARDS [117].
Nucleotide oligomerization domain (NOD)-like
receptors (NLRs)
Another class of PRRs is the NOD-like receptors.
These receptors exist intracellularly and serve to acti-
vate caspase-1 and initiate an inflammatory response
triggered by intracellular PAMPs [126]. NLRs are
known to respond to a variety of PAMPs, includ-
ing the bacterial cell wall components peptidogly-
can and muramyl dipeptide (MDP), bacterial flag-
ellin and other bacterial toxins [126–128]. NLRs have
also been shown to respond to two classes of non-
infectious stimuli, DAMPS and environmental insults
[126]. Environmental insults such as silica and asbestos
have been shown to induce inflammation in a NLR3-
dependent manner [129]. The strongest evidence for
DAMP-induced NLR activation comes from a study
of uric acid and NOD-like receptor 3 (NLR3). Uric
acid is known to be released from dying cells [130].
Researchers noted a brisk IL-1β response when mono-
cytes were incubated with monosodium urate (MSU).
This interaction was dependent on ASC (a necessary
NLR co-factor), providing compelling evidence that
the IL-1β response was mediated through NLR path-
way signalling. Moreover, the inflammatory response
induced by MSU was abrogated in NLR3 (Nlrp3)-
deficient mice [131]. Similarly, uric acid appears to
mediate lung inflammation in bleomycin-induced lung
injury, as reduced lung injury is observed in mice with
decreased uric acid production (by xanthine oxidase
administration) or in mice genetically lacking NLR3
[132]. Hyaluronan, which was previously shown to
activate the TLR pathway, has more recently been dis-
covered to be a NLR3 ligand, including causing IL-1β
release in peritoneal macrophages [133]. This is the
first description of a DAMP that is capable of activat-
ing both the TLR and NLR pathways.
Conclusions
TLRs are central mediators of the pathophysiological
events that occur in both infectious and non-infectious
lung injury. While much investigation has focused
on external triggers of ALI, emerging data illuminate
the critical role of endogenous danger signals in
modulating the lung injury response. These DAMPs
originate from multiple sources, such as injured and
dying cells or the ECM, or exist as immunomodulatory
proteins within the airspace and interstitium. DAMPs
can function as either TLR agonists or antagonists, and
can modulate both TLR and NLR signalling cascades.
Additional research is needed to define the contribution
of DAMPs in fibroproliferative processes, including
the proliferative phase of ALI. Regardless, DAMPS
may represent an important therapeutic target in the
prevention and/or treatment of ALI/ARDS.
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